Galmed and Tissue Dynamics Unveil New Pathway, Aramchol Combo Cuts Cardiac Fibrosis Fourfold
GLMD•Tissue Dynamics and Galmed discovered a human-specific metabolic mechanism driving cardiac fibrosis using organoid models and showed that Aramchol Meglumine plus a PPARα agonist reduced fibrotic burden by approximately fourfold (p<0.001). A new patent application was filed to support upcoming IND-enabling activities for Galmed’s cardiometabolic development program.
1. Identification of human-specific metabolic pathway
Tissue Dynamics employed its DynamiX® platform and advanced human cardiac organoid models to reveal a previously unrecognized metabolic mechanism involving mitochondrial stress and lipogenesis that drives cardiac fibrosis and heart failure, a process undetectable in conventional animal studies.
2. Efficacy of Aramchol Meglumine and PPARα combination
In inflammatory human cardiac organoids, the combination of Aramchol Meglumine, an SCD1 inhibitor, and a selective PPARα agonist achieved an approximate fourfold reduction in fibrotic burden (p<0.001) while preserving cardiac muscle density and metabolic function.
3. Patent filing and development plan
Based on these findings, a new patent application was filed and preparations are underway to support IND-enabling activities, positioning Galmed to advance its cardiometabolic program into clinical development.
